January 15, 2018

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients


CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2

Lung cancer is the number one cause of cancer-related deaths in the United States.  Research identifying specific molecular and genetic components of a patient’s cancer cells has led to the discovery of new therapeutic agents that target and treat lung cancers based on their individual characteristics.

The EGFR is involved in cellular replication and growth. A mutation within the EGFR can lead to the development and spread of cancer cells. Patients with cancer that has an EGFR mutation often respond well to EGFR inhibitors – agents that block the effects of the mutated EGFR. However, patients with the EGFR T790M mutation tend to either not respond, or become quickly resistant to treatment with the currently approved EGFR inhibitors.

About Tagrisso

Tagrisso is a 3rd generation, EGFR- tyrosine kinase inhibitor (TKI) medication that potently and selectively inhibits both EGFRm and EGFR T790M resistance mutations. EGFR mutations occur in 30–40% of NSCLC in Asian populations compared to 10–15% in Western populations.

The current clinical trail compared treatment with Tagrisso to standard treatment with erlotinib or gefitinib as first line therapy in 556 patients from Asia, Europe, and North America with NSCLC and EGFR mutations.

Overall treatment with Tagrisso improved progression-free survival by 54%.  The overall response to treatment was 80% with Tagrisso compared to 75% with standard of care treatment.  The average duration of response was two-fold higher for patients treated with Tagrisso (17.6 months) compared to standard of care (8.7 months). The median progression-free survival was 16.5 months with Tagrisso compared to 11.0 months for the standard therapy.

In sum, Tagrisso provided a significant progression-free survival benefit in Asian patients with EGFR-mutated NSCLC. Tagrisso should be the preferred first line treatment for EGFR-mutant NSCLC in Asia.”


  1. Abstract LBA6_PR ‘Tagrisso vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset‘ will be presented by Byoung Chul Cho during the Mini Oral session Thoracic malignancies 2 on Sunday, 19 November 2017, 14:30 to 15:25 (SGT) in Room 310. Annals of Oncology, Volume 28, 2017 Supplement 10
  2. ‘Tagrisso in treatment-naïve EGFR mutation-positive advanced NSCLC (FLAURA)’ S Ramalingam et al, The New England Journal of Medicine (NEJM), 10.1056/NEJMoa1713137, http://www.nejm.org/doi/full/10.1056/NEJMoa1713137

Copyright © 2018 CancerConnect. All Rights Reserved.

Tags: EGFR-TKI, first-line treatment, Lung Cancer, News, non-small cell lung cancer, nsclc, osmertinib, tagrisso, Uncategorized